NO985326L - Bifenylsulfonamid matriksmetalloproteinase-inhibitorer - Google Patents

Bifenylsulfonamid matriksmetalloproteinase-inhibitorer

Info

Publication number
NO985326L
NO985326L NO985326A NO985326A NO985326L NO 985326 L NO985326 L NO 985326L NO 985326 A NO985326 A NO 985326A NO 985326 A NO985326 A NO 985326A NO 985326 L NO985326 L NO 985326L
Authority
NO
Norway
Prior art keywords
matrix metalloproteinase
metalloproteinase inhibitors
alkyl
biphenylsulfonamide
biphenylsulfonamide matrix
Prior art date
Application number
NO985326A
Other languages
English (en)
Other versions
NO312510B1 (no
NO985326D0 (no
Inventor
Patrick Michael O'brien
Drago Robert Sliskovic
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO985326D0 publication Critical patent/NO985326D0/no
Publication of NO985326L publication Critical patent/NO985326L/no
Publication of NO312510B1 publication Critical patent/NO312510B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
NO19985326A 1996-05-17 1998-11-16 Bifenylsulfonamid matriksmetalloproteinase-inhibitorer, anvendelse derav, samt farmasöytiske formuleringer omfattende dem NO312510B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1746096P 1996-05-17 1996-05-17
PCT/US1997/006801 WO1997044315A1 (en) 1996-05-17 1997-04-24 Biphenylsulfonamide matrix metalloproteinase inhibitors

Publications (3)

Publication Number Publication Date
NO985326D0 NO985326D0 (no) 1998-11-16
NO985326L true NO985326L (no) 1999-01-14
NO312510B1 NO312510B1 (no) 2002-05-21

Family

ID=21782716

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19985326A NO312510B1 (no) 1996-05-17 1998-11-16 Bifenylsulfonamid matriksmetalloproteinase-inhibitorer, anvendelse derav, samt farmasöytiske formuleringer omfattende dem

Country Status (23)

Country Link
EP (1) EP0901466B1 (no)
JP (1) JP2000511175A (no)
KR (1) KR20000011095A (no)
CN (1) CN1077885C (no)
AT (1) ATE207891T1 (no)
BG (1) BG63940B1 (no)
BR (1) BR9710841A (no)
CA (1) CA2253342A1 (no)
CZ (1) CZ294063B6 (no)
DE (1) DE69707865T2 (no)
DK (1) DK0901466T3 (no)
EA (1) EA001561B1 (no)
EE (1) EE03965B1 (no)
ES (1) ES2167733T3 (no)
HK (1) HK1019585A1 (no)
IL (1) IL126832A0 (no)
NO (1) NO312510B1 (no)
NZ (1) NZ332711A (no)
PL (1) PL186416B1 (no)
PT (1) PT901466E (no)
SK (1) SK282863B6 (no)
WO (1) WO1997044315A1 (no)
ZA (1) ZA974223B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2193691A1 (en) * 1994-06-22 1995-12-28 Andrew Miller Metalloproteinase inhibitors
US6124333A (en) * 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
BR9714385A (pt) * 1996-12-09 2000-05-16 Warner Lambert Co Método para tratamento e prevenção de deficiência cardìaca e dilatação ventricular
EP1366765A1 (en) * 1996-12-17 2003-12-03 Warner-Lambert Company Llc Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
US6340709B1 (en) * 1996-12-17 2002-01-22 Warner-Lambert Company Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
GB9706255D0 (en) * 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
RU2207849C2 (ru) * 1997-07-22 2003-07-10 Шионоги & Ко., Лтд. Композиция для лечения и профилактики гломерулопатии, новые соединения, в нее входящие, фармацевтическая композиция для ингибирования матриксных металлопротеиназ и композиция для ингибирования коллагеназ типа iv
NZ503962A (en) * 1997-12-23 2002-03-28 Warner Lambert Co ACE inhibitor (angiotensin converting enzyme) and MMP (matrix metalloproteinase inhibitor) combinations for treating fibrosis
TR200002224T2 (tr) * 1998-02-04 2000-12-21 Novartis Ag Matris-bozucu metalloproteinasları inhibe eden sülfonilamino türevleri.
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
KR20010041916A (ko) * 1998-03-17 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제
EP0967201A1 (en) * 1998-05-20 1999-12-29 Roche Diagnostics GmbH Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors
ES2187171T3 (es) * 1998-07-16 2003-05-16 Aventis Pharma Gmbh Derivados de acidos fosfinico y fosfonico en calidad de medicamentos.
EA200100153A1 (ru) * 1998-07-21 2001-08-27 Варнер-Ламберт Компани Совместное назначение ингибиторов асат и ммр для лечения атеросклеротических поражений
DE19851184A1 (de) * 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
PL351374A1 (en) * 1999-04-19 2003-04-07 Shionogi & Co Sulfonamide derivatives having oxadiazole rings
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
EP1249233B9 (en) 1999-11-26 2009-08-05 Shionogi & Co., Ltd. Npyy5 antagonists
KR20030030036A (ko) * 2000-09-29 2003-04-16 시오노기세이야쿠가부시키가이샤 티아졸 또는 옥사졸 유도체
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
JP4219810B2 (ja) * 2001-10-26 2009-02-04 塩野義製薬株式会社 Mmp阻害作用を有するスルホンアミド誘導体
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
CA2548513A1 (en) * 2003-12-04 2005-07-07 Wyeth Biaryl sulfonamides and methods for using same
EP1735274B1 (en) 2004-03-22 2009-11-25 Southern Research Institute Nonpeptide inhibitors of matrix metalloproteinases
CN101279956B (zh) * 2008-04-25 2011-06-15 南昌大学 一种基质金属蛋白酶抑制剂及合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
CA2193691A1 (en) * 1994-06-22 1995-12-28 Andrew Miller Metalloproteinase inhibitors

Also Published As

Publication number Publication date
CN1219166A (zh) 1999-06-09
BG102918A (en) 1999-09-30
CN1077885C (zh) 2002-01-16
NZ332711A (en) 2000-06-23
CZ294063B6 (cs) 2004-09-15
WO1997044315A1 (en) 1997-11-27
EE03965B1 (et) 2003-02-17
SK282863B6 (sk) 2002-12-03
EP0901466B1 (en) 2001-10-31
SK157798A3 (en) 1999-04-13
ZA974223B (en) 1997-12-10
EA199800988A1 (ru) 1999-04-29
NO312510B1 (no) 2002-05-21
EA001561B1 (ru) 2001-04-23
PT901466E (pt) 2002-04-29
DE69707865D1 (de) 2001-12-06
ATE207891T1 (de) 2001-11-15
EE9800397A (et) 1999-06-15
AU713286B2 (en) 1999-11-25
IL126832A0 (en) 1999-08-17
ES2167733T3 (es) 2002-05-16
BR9710841A (pt) 1999-08-17
DK0901466T3 (da) 2002-02-18
JP2000511175A (ja) 2000-08-29
PL186416B1 (pl) 2004-01-30
CA2253342A1 (en) 1997-11-27
BG63940B1 (bg) 2003-07-31
DE69707865T2 (de) 2002-05-02
EP0901466A1 (en) 1999-03-17
HK1019585A1 (en) 2000-02-18
NO985326D0 (no) 1998-11-16
CZ366898A3 (cs) 1999-02-17
KR20000011095A (ko) 2000-02-25
PL329929A1 (en) 1999-04-26
AU2680397A (en) 1997-12-09

Similar Documents

Publication Publication Date Title
ATE207891T1 (de) Biphenylsulfonamid matrix metalloproteinase inhibitoren
AU6894800A (en) Caspase inhibitors and uses thereof
GB9801690D0 (en) Therapeutic agents
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
WO2003024448A3 (en) Inhibitors of histone deacetylase
ATE289590T1 (de) Beta-sulfonyl-hydroxamsäuren als matrix- metalloproteinaseinhibitoren
DE69612003D1 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
FI971412A0 (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
EA200101085A1 (ru) Гидроксамовые кислоты, производные ароматических сульфонов, - ингибиторы металлопротеаз
EA200100804A1 (ru) Сульфоароматические производные гидроксамовой кислоты как ингибиторы металлопротеаз
DK0946166T3 (da) Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling
PT1250340E (pt) Metodos e compostos para inibicao de mrp1
NZ333550A (en) Matrix metalloproteinase inhibitors for inhibiting the release of TNF
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
DE69736945D1 (de) Biphenylverbindungen sowie ihre anwendung als östrogene mittel
CY2225B1 (en) Organic compounds
ATE282602T1 (de) Buttersäure matrix-metalloproteinase-inhibitoren
BR0214886A (pt) Fenilalquinos
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees